Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Antibody profiles of internal viral proteins predict severe COVID-19 outcomes

Most research on immunity to the SARS-CoV-2 virus and COVID-19 vaccine development has focused on antibody responses to the spike protein and other viral surface proteins.

24 Jun 2022

Serologic testing captures missed children at risk for long Covid

A new study provides evidence of the utility of serologic testing in helping to pick up children with long Covid following missed diagnoses of COVID-19.

24 Jun 2022

Natural and hybrid immunity dynamics in South African mothers

Researchers evaluated natural and hybrid immunity after four COVID-19 waves in South Africa.

24 Jun 2022

Epstein-Barr virus can reactivate in long COVID

In a recent study posted to the medRxiv* preprint server, researchers at the University of California, San Francisco, and Monogram Biosciences examined the connections between the post-acute sequelae of coronavirus disease 2019 (COVID-19) (PASC) and Epstein-Barr virus (EBV) reactivation.

23 Jun 2022

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

A recent article posted to the bioRxiv* preprint server identified numerous efficacious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies from convalescent SARS-CoV-2 patients.

23 Jun 2022

Researchers discover two important novel aspects of APOE4 gene in Alzheimer's patients

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the most common cause of dementia, affecting more than 5.8 million individuals in the U.S.

23 Jun 2022

Correlates of anamnestic humoral immunity throughout SARS-CoV-2 variants of concern

A recent work posted to the bioRxiv* preprint server assessed the indicators of anamnestic humoral immunity among the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs).

23 Jun 2022

Analyzing biophysical restrictions of SARS-CoV-2 N-terminal domain

In a recent article posted to the bioRxiv* preprint server, researchers at the University of Illinois at Urbana-Champaign, Scripps Research Institute, and Case Western Reserve University evaluated the biophysical limitations of the spike (S) N-terminal domain (NTD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

23 Jun 2022

Lung cancer patients treated with immune checkpoint inhibitors can be safely vaccinated against COVID-19, study says

Cancer patients have received priority status to receive COVID-19 vaccinations but there is limited data regarding the safety and efficacy of the vaccines for patients treated for lung cancer with immune checkpoint inhibitors.

22 Jun 2022

Wearable activity trackers combined with AI may aid in early identification of COVID-19

Wearable activity trackers that monitor changes in skin temperature and heart and breathing rates, combined with artificial intelligence (AI), might be used to pick up COVID-19 infection days before symptoms start, suggests preliminary research published in the open access journal BMJ Open.

22 Jun 2022

COVID-19 outcomes improved for SARDs patients through Omicron wave

In a recent study posted to the medRxiv* pre-print server, researchers investigated coronavirus disease 2019 (COVID-19) incidence and severity among systemic autoimmune rheumatic diseases (SARDs) patients in Massachusetts, United States (US), between March 1, 2020, and January 31, 2022.

22 Jun 2022

A longitudinal population-based study of COVID-19 in the UK

In a recent study posted to the medRxiv* pre-print server, researchers identified potential risk factors and incident symptoms of coronavirus disease 2019 (COVID-19) in the general population of the United Kingdom (UK).

21 Jun 2022

Insufficient drug exposure most likely to cause COVID-19 rebound

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals.

21 Jun 2022

Researchers compare the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection

Researchers comparatively assessed the generation of B lymphocyte-mediated antibody responses and T lymphocyte-mediated cellular responses between mRNA BNT162b vaccinees and mild COVID-19 patients.

21 Jun 2022

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

A new study reported four cases of Myelin Oligodendrocyte Glycoprotein-Associated Disorder that commenced after SARS-CoV-2 infection.

21 Jun 2022

The impact of epistatic interactions on the ACE2 affinity in the SARS-CoV-2 Omicron variant

Researchers assessed the impact of epistatic interactions on the ACE2 affinity in the SARS-CoV-2 Omicron variant.

21 Jun 2022

After maternal COVID vaccination, infants have persistent anti-SARS-CoV-2 antibodies at 3 months

A recent article published in the journal Clinical Infectious Diseases assessed the kinetics of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies derived from mothers among infants in association with the timing of prenatal SARS-CoV-2 vaccination.

21 Jun 2022

Real-world study shows Paxlovid associated with lower hospitalization rates

In a recent study posted to the medRxiv* pre-print server, researchers investigated the effectiveness of nirmatrelvir plus ritonavir in preventing hospitalizations among individuals aged 50 or older and vaccinated for coronavirus disease 2019 (COVID-19).

20 Jun 2022

Researchers assess monkeypox clinical management guidelines worldwide

A new study demonstrated the scarcity of appropriate clinical management guidelines for monkeypox infections across the globe.

20 Jun 2022

SARS-CoV-2 spike circulating in most long COVID 12 months post-diagnosis

In a recent study posted to the medRxiv* preprint server, researchers explored the association between circulating coronavirus disease 2019 (COVID-19) antigens and post-COVID-19 sequelae (long COVID).

20 Jun 2022

Antibody News and Research

Further Reading

Antibody profiles of internal viral proteins predict severe COVID-19 outcomes

Serologic testing captures missed children at risk for long Covid

Natural and hybrid immunity dynamics in South African mothers

Epstein-Barr virus can reactivate in long COVID

Fragment crystallizable-altered COVID-19 antibodies efficacious across two animal models

Researchers discover two important novel aspects of APOE4 gene in Alzheimer's patients

Correlates of anamnestic humoral immunity throughout SARS-CoV-2 variants of concern

Analyzing biophysical restrictions of SARS-CoV-2 N-terminal domain

Lung cancer patients treated with immune checkpoint inhibitors can be safely vaccinated against COVID-19, study says

Wearable activity trackers combined with AI may aid in early identification of COVID-19

COVID-19 outcomes improved for SARDs patients through Omicron wave

A longitudinal population-based study of COVID-19 in the UK

Insufficient drug exposure most likely to cause COVID-19 rebound

Researchers compare the development and persistence of antibody and T-cell responses elicited by the mRNA BNT162b2 vaccine or SARS-CoV-2 infection

SARS-CoV-2 infection may be a trigger of myelin oligodendrocyte glycoprotein-associated disorder

The impact of epistatic interactions on the ACE2 affinity in the SARS-CoV-2 Omicron variant

After maternal COVID vaccination, infants have persistent anti-SARS-CoV-2 antibodies at 3 months

Real-world study shows Paxlovid associated with lower hospitalization rates

Researchers assess monkeypox clinical management guidelines worldwide

SARS-CoV-2 spike circulating in most long COVID 12 months post-diagnosis

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo